Markets
Stocks
Funds
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
(OB: )
N/A   UNCHANGED
Last Price  /  Updated:   /  Add to My Watchlist      
View: Quote News Research
Price and Volume
Detailed Quote
Chart for (: )
 
Intraday
1 Week
1 Month
3 Month
1 Year
  
Compare to:
Volume 0
Open -
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close -
Today's Range N/A - N/A
52wk Range N/A - N/A
Shares Outstanding N/A
Dividend Yield N/A
Performance
Top News
More News
TG Therapeutics, Inc. to Present at Upcoming Investor Conferences
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced its participation at two upcoming investor conferences. Michael S. Weiss, the Company’s Executive Chairman and Chief Executive Officer, is scheduled... Read More
from GlobeNewswire News Releases
TG Therapeutics, Inc. Announces the Phase 3 ULTIMATE Trials Evaluating TG-1101 in Patients with Multiple Sclerosis Are Now Open for Enrollment
TG Therapeutics, Inc. (NASDAQ:TGTX) today announced that enrollment is now open for the Phase 3 ULTIMATE I and II trials. ULTIMATE I and II are two independent Phase 3 clinical trials evaluating the... Read More
from GlobeNewswire News Releases
More News
Read More
TG Therapeutics Announces Completion of Target Enrollment in the UNITY-CLL Phase 3 Trial
from GlobeNewswire News Releases
TG Therapeutics, Inc. Announces Clinical Data Presentations at the Upcoming 7th Joint ECTRIMS – ACTRIMS Meeting
from GlobeNewswire News Releases
TG Therapeutics, Inc. Announces Successful Outcome from the First Pre-Planned Interim Analysis by Independent DSMB of the DLBCL Cohort in the UNITY-NHL Phase 2b Trial
from GlobeNewswire News Releases
TG Therapeutics, Inc. Provides Business Update and Reports Second Quarter 2017 Financial Results
from GlobeNewswire News Releases
TG Therapeutics, Inc. to Host Conference Call on Second Quarter 2017 Financial Results and Business Update
from GlobeNewswire News Releases
TG Therapeutics Announces Special Protocol Assessment (SPA) Agreement with the FDA for a Phase 3 Program of TG-1101 (ublituximab) for Patients with Multiple Sclerosis (MS)
from GlobeNewswire News Releases
Technical Reports on Biotech Equities -- Opko Health, Array BioPharma, Immunomedics, and TG Therapeutics
from PR Newswire
BRIEF-TG Therapeutics says phase 3 ULTIMATE trials evaluating TG-1101 in multiple sclerosis patients are now open for enrollment
category companyNews
from Reuters: Company News
Sum Up The Parts: XBI Could Be Worth $104
category ETFs
from ETF Channel
Stock Market JSON API provided by www.cloudquote.net
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial